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Introduction: Tumor necrosis factor-inducible gene 6 protein (TSG-6), one of the cytokines released by human
mesenchymal stem/stromal cells (hMSC), has an anti-inflammatory effect and alleviates several pathological conditions;
however, the hepatoprotective potential of TSG-6 remains unclear. We investigated whether TSG-6 promoted liver
regeneration in acute liver failure.
Methods: The immortalized hMSC (B10) constitutively over-expressing TSG-6 or empty plasmid (NC: Negative Control) were
established, and either TSG-6 or NC-conditioned medium (CM) was intraperitoneally injected into mice with acute liver
damage caused by CCl4. Mice were sacrificed at 3 days post-CM treatment.
Results: Higher expression and the immunosuppressive activity of TSG-6 were observed in CM from TSG-6-hMSC. The
obvious histomorphological liver injury and increased level of liver enzymes were shown in CCl4-treated mice with or
without NC-CM, whereas those observations were markedly ameliorated in TSG-6-CM-treated mice with CCl4. Ki67-positive
hepatocytic cells were accumulated in the liver of the CCl4 + TSG-6 group. RNA analysis showed the decrease in both of
inflammation markers, tnfα, il-1β, cxcl1 and cxcl2, and fibrotic markers, tgf-β1, α-sma and collagen α1, in the CCl4 + TSG-6
group, compared to the CCl4 or the CCl4 + NC group. Protein analysis confirmed the lower expression of TGF-β1 and
α-SMA in the CCl4 + TSG-6 than the CCl4 or the CCl4 + NC group. Immunostaining for α-SMA also revealed the
accumulation of the activated hepatic stellate cells in the livers of mice in the CCl4 and CCl4 + NC groups, but not in the
livers of mice from the CCl4 + TSG-6 group. The cultured LX2 cells, human hepatic stellate cell line, in TSG-6-CM showed
the reduced expression of fibrotic markers, tgf-β1, vimentin and collagen α1, whereas the addition of the TSG-6 antibody
neutralized the inhibitory effect of TSG-6 on the activation of LX2 cells. In addition, cytoplasmic lipid drops, the marker of
inactivated hepatic stellate cell, were detected in TSG-6-CM-cultured LX2 cells, only. The suppressed TSG-6 activity by TSG-6
antibody attenuated the restoration process in livers of TSG-6-CM-treated mice with CCl4.
Conclusions: These results demonstrated that TSG-6 contributed to the liver regeneration by suppressing the activation of
hepatic stellate cells in CCl4-treated mice, suggesting the therapeutic potential of TSG-6 for acute liver failure.Introduction
Acute liver failure and chronic liver disease are life-
threatening diseases for which liver transplantation is
the only permanent remedy. However, the number of
available organs from donors is vastly insufficient for the
number of patients requiring such procedures. Even if
transplant patients receive a whole liver transplantation,
several post-transplant complications may arise, such as
immune rejection response and death of the donor or* Correspondence: hjcha@sogang.ac.kr; y.jung@pusan.ac.kr
3Department of Life Science, Sogang University, Seoul 121-742, Korea
1Department of Intergrated Biological Science, Pusan National University,
63-2 Pusandaehak-ro, Kumjeong-gu, Pusan 609-735, Korea
Full list of author information is available at the end of the article
© 2015 Wang et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.recipient in worst-case scenarios [1]. Therefore, exten-
sive studies are being conducted to develop new treat-
ments for liver diseases, and stem cell based therapy has
been suggested as an alternative treatment strategy for
patients who suffer from various hepatic diseases [2].
Mesenchymal stem cells (MSCs) found in most adult and
postnatal organs are capable of self-renewing and differenti-
ating into several lineages of cells, including hepatocytes
[3,4]. This differentiation potential of MSCs into hepato-
cytes provides new and promising therapeutics for patients
with liver disease. These therapeutic effects of MSCs in the
treatment of liver disease have been reported both in ani-
mal and clinical studies [5]. In those studies, MSCs were
shown to contribute to liver regeneration by secretingThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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there are still a number of technical limitations or possible
undesirable side effects associated with the therapeutic ap-
plication of MSCs to patients with end-stage liver diseases
[8]. In particular, engrafted MSCs can differentiate into not
only hepatocytes but also myofibroblasts, a main source of
collagen fiber in a fibrotic liver, depending on the timeframe
of differentiation and route of MSC injection [9]. Hence,
further characterization of MSCs may be critical for ensur-
ing the safety of MSC-based cell therapy. The beneficial
effect of MSC transplantation is based on autologous
transplantation. However, it is difficult to try MSC trans-
plantation with patients with end-stage liver disease [9].
Although allogeneic stem cell transplantation might be
more effective for these patients, it also brings several ob-
stacles, such as immune rejection or engraftment of virus-
carrying MSCs [1]. The paracrine effect, which results
from biologically active soluble factors secreted from hu-
man MSCs (hMSCs), such as angiopoietin-1, interleukin-
10, keratinocyte growth factor, and so on, has been shown
to be therapeutically valid in both animal and clinical
studies [10,11]. Since many kinds of tropic and immuno-
modulatory factors secreted from MSCs are also known to
create a favorable micro-environment for liver regener-
ation [9], it is necessary to identify and characterize such
biologically active soluble factors.
Tumor necrosis factor-inducible gene 6 protein (TSG-6),
a 35 kDa glycoprotein [12], was identified as an inflamma-
tory factor as its expression increased in response to in-
flammatory mediators [13]. However, upregulated TSG-6
during the inflammatory process has been shown to con-
tribute to modulate the inflammatory response in adverse
[13]. Recent studies demonstrate that TSG-6 is identified
as an important immune modulator secreted from hMSCs
and shown to be responsible for hMSCs’ therapeutic ef-
fects, such as improvement of cardiac function, peritonitis
and wound healing [14]. However, these associations of
TSG-6 with response in the liver are unknown.
Liver inflammation occurs in response to damage [15].
Liver injuries stimulate the repair response, such as prolif-
eration of hepatocytes and inflammation, and a successful
repair response reconstitutes a functional liver [16]. How-
ever, continued damage perpetuates injury and promotes
progressive fibrogenesis [16]. Liver inflammation also ac-
celerates fibrosis [17]. Several inflammatory factors, such
as tumor necrosis factor (TNF-α) and interleukin (Il) -1β,
and Il-6, secreted by inflammatory cells are involved in
the recruitment of circulating macrophages into the liver
and the transition of hepatic stellate cells into myofibro-
blasts [18]. This progressive fibrogenesis ends with death
from cirrhosis and/or liver cancer [19]. Thus, the modula-
tion of liver inflammation in this setting is a key target for
reducing fibrosis. For this reason, we hypothesized that
TSG-6 could influence liver regeneration by reducinginflammation and fibrosis because TSG-6 exerts an anti-
inflammatory effect. To prove our hypothesis, we made
immortalized hMSCs stably expressing TSG-6. Due to
constant secretion of TSG-6 from hMSCs in the condi-
tioned medium (CM), TSG-6-rich CM could be readily
applied to mice with acute liver injury caused by CCl4.
Our results showed that TSG-6 promoted liver regener-
ation by decreasing fibrosis.
Methods
Generation of hMSCs stably expressing TSG-6
We sub-cloned P/I-TSG-6 (kindly provided by Dr. Tae-
Hee Lee in Yonsei Univ.) into a CSII-EF-MCS vector.
hMSCs stably expressing TSG-6, were generated as pre-
viously reported [20]. In detail, each viral plasmid (3 μg)
(CSII-EF-MCS and CSII-EF-TSG-6) was transfected into
293FT cells with pLP1, pLP2, pLP/VSVG, using lipofec-
tamine 2000 (cat. #11668-027, Life Technologies, Inc.
Grand Island, NY, USA). After 48 hours, the culture
media containing the lenti-viruses were collected from
the transfected 293FT cells. Virus medium was filtered
(0.45 μm filter, EMD Millipore, Billerica, MA, USA) and
then treated to hMSCs for an additional 24 hours in the
presence of 4 μg/ml of polybrene (Sigma–Aldrich, St.
Louis, MO, USA). B10-hMSCs were maintained as de-
scribed previously [21].
Preparation of conditioned media
For preparation of CM, cells were seeded at more than
90% confluence. The next day, cells were washed with
PBS twice, changed to 0.2% fetal bovine serum (FBS)-
containing media and incubated for another three days.
CM were further concentrated with YM-10 (Millipore,
Cat. No. 4205).
Immune suppression assay
Splenocytes, 1.5 × 106 per well (24-well) (freshly isolated
from C57BL6 female mice as described previously [22]),
were cultured with or without CM supplement for three
days. To stimulate T cells, 1 μg/ml of anti-CD3ε (2C11)
(BD Pharmingen, San Jose, CA, USA) was added. Cells
were fluorescence labeled with carboxyfluorescein succini-
midyl ester (CFSE) and then proliferation after activation
was determined by flow cytometry (BD, FACS Calibur™).
Animal studies
Six-week old male C57BL6 mice were purchased from
Hyochang (Dae-gu, Korea), fed with a normal diet, watered,
and housed with a 12 hour light-dark cycle. In vivo experi-
ments were performed as previously described. Mice were
seven weeks of age and weighed an average of 21 g at the
start of the experiments. To induce acute liver injury, mice
received CCl4 (1.0 mg/kg body weight) (n = 15) intraperito-
neally twice for one week as previously described [23]. As
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hicle (CTRL) (n = 4) intraperitoneally. Those mice were
then injected i.p. with 0.5 ml CM from TSG-6 overexpress-
ing MSCs (TSG-6) (n = 6), or empty plasmid-carrying
MSCs (NC; negative control) (n = 5) at day 8, and sacrificed
at day 3 following the medium treatment (Figure 1A). To
examine the specificity of TSG-6 for liver, TSG-6-CM was
incubated with TSG-6 antibody (10 μg/ml) (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) or control immuno-
globulin G (IgG) (10 μg/ml) (Sigma-Aldrich) for one hour
at room temperature, and 0.5 ml of these CMs was injected
into CCl4-treated mice (TSG-6-CM+TSG-6 antibody
group: n = 5/ TSG-6-CM+ IgG group: n = 5) (Figure 1B).
Animal care and surgical procedures were approved by
the Pusan National University Institutional Animal Care
and Use Committee and carried out in accordance with
the provisions of the National Institutes of Health Guide
for the Care and Use of Laboratory Animals.
Measurement of AST/ALT
Serum aspartate aminotransferase (AST) and alanine ami-
notransferase (ALT) were measured using Chemi Lab
GOT/GPT (IVD Lab Co., Korea) according to the manu-
facturer’s instructions.
Liver histology and immunohistochemistry
Liver specimens were fixed in 10% neutral buffered forma-
lin, embedded in paraffin and cut into 4 μm sections. Speci-
mens were dewaxed, hydrated, and stained in the usual
manner with standard hematoxylin and eosin (H & E) to
examine morphology. For immunohistochemistry (IHC),
sections were incubated for 10 minutes in 3% hydrogen
peroxide to block endogenous peroxidase. Antigen retrieval
was performed by heating in 10 mM sodium citrate buffer
(pH 6.0) or incubating with pepsin for 10 minutes. After
washing with TBS, sections were treated with Dako protein
block (X9090; Dako Envision, Carpinteria, CA) for 30 mi-
nutes and incubated with primary antibody Ki67 (NCL-Figure 1 Design of mouse experimental model. (A) After being i.p. inje
treated with NC-CM or TSG-6-CM, one time at eight days. These mice were
neutralized TSG-6-CM by TSG-6 antibody or the TSG-6-CM + IgG antibody. T
CTRL, control; IgG, immunoglobulin G; i.p., intraperitoneally; NC, negative coKi67, Novocastra, Leica Microsystems, Newcastle, Upon
Tyne, UK), pancytokeratin (PanCK) (Z0622; Dako), Sox9
(AB5535; Millipore), or α-Sma (ab5694; Abcam, Cambridge,
Massachusetts, USA), at 4°C overnight. Other sections were
also incubated at 4°C overnight in non-immune sera to
demonstrate staining specificity. Polymer horseradish per-
oxidase (HRP) anti-rabbit (K 4003; Dako) or anti-mouse
(K 4001; Dako) was used as secondary antinody. 3,3′-
Diaminobenzidine (DAB) was employed in the detection
procedure.
Cell counting
To quantify the number of Ki67-positive cells, 10 central
vein (CV) areas were randomly selected per section at ×
40 magnification for each mouse. CV chosen for analysis
ranged from 90 to 150 μm. The Ki67-positive cells were
quantified by counting the total number of Ki67-positive
cells per field.
Quantitative real-time PCR
Total RNA which had been stored at -80°C was extracted
with TRIZOL™ (Ambion® by Life Technologies). After as-
suring RNA quality and concentration, gene expression
was evaluated by QRT-PCR analysis. mRNAs were quanti-
fied by real-time RT-PCR according to the manufacturer’s
specifications (Eppendorf, Mastercycler Real-TIme PCR,
Effendorf Korea Ltd., Seoul, Korea). The sequences of
primers for mice are listed in Table 1. Samples were ana-
lyzed in duplicate according to the ΔΔCt method. All PCR
products were directly sequenced for genetic confirmation
in Macrogen Inc (Korea).
Western blot assay
Total protein was extracted from freeze-clamped liver tis-
sue samples that had been stored at -80°C. Whole tissues
were homogenized in RIPA (78510; Thermo, Rockford, IL)
supplemented with protease inhibitors (Complete Mini 11
836 153 001; Roche, Indianapolis, IN). Equal amounts ofcted with CCl4 or corn oil (CTRL) twice for one week, mice were
sacrificed at 11 days. (B) CCl4-treated mice were injected with the
hese mice were also sacrificed at 11 days. CM, conditioned medium;
ntrol; TSG-6, tumor necrosis factor-inducible gene 6 protein.
Table 1 Sequences of primers used for QRT-PCR
Mouse









9 s GACTCCGGAACAAACGTGAGG CTTCATCTTGCCCTCGTCCA
Rat
Gene Forward Sequence Reverse Sequence
tsg-6 AGTGATGCGTCCGTCACAGCC AGATGGCTAAACCGTCCAGCTAAGA
9 s GACTCCGGAACAAACGTGAGGT CTTCATCTTGCCCTCGTCCA
Human
Gene Forward sequence Reverse sequence
tgf-β1 TTGACTGAGTTGCGATAATGTT GGGAAATTGCTCGACGAT
vimentin CGAAAACACCCTGCAATCTT GTGAGGTCAGGCTTGGAAAC
collagen α1 CAGATCACGTCATCGCACAA TGTGAGGCCACGCATGAG
9 s GACTCCGGAACAAACGTGAGGT CTTCATCTTGCCCTCGTCCA
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gel electrophoresis and transferred to polyvinylidene
difluoride (PVDF) membranes. Primary antibodies against
TGF-β (3711S; Cell Signaling) and α-Sma (A5228-200UL;
Sigma-Aldrich) were used in this experiment. Membranes
were developed by chemiluminescence (ATTO Corporation,
Tokyo, Japan). The blots that were obtained from three in-
dependent experiments were scanned and a region of
interest (ROI) around the band of interest was defined.
Band intensities were calculated by using the CS analyzer
2.0 program (ATTO Corporation).
Cell experiments
The human hepatic stellate cell line LX2, a well-
characterized cell line derived from human hepatic stel-
late cells [24], B10-NC and B10-TSG-6 were cultured at
a density of 2 × 106 in Minimum Essential Medium
alpha (MEM α, Gibco, Life Technologies) supplemented
with 10% FBS (Gibco, Life Technologies, Grand Island,
NY) and 1X antibiotics at 37°C in a humidified atmos-
phere containing 5% CO2. LX2 was a generous gift from
Won-il Jung (Korea Advanced Institute of Science and
Technology). When B10-NC or B10-TSG-6 cells were
70% to 80% confluent, CM of these cells were collected
to treat LX2. For biochemical analysis of gene expression
changes, LX2 at 70% to 80% confluence were starved in
medium containing no FBS for six hours. Activation ofLX2 was verified by examining the expression of pro-
fibrotic signaling genes at 24 and 48 hours after addition
of FBS. Based on the gene expression data, we consid-
ered LX2 as fully activated cells at 48 hours (data not
shown). Fully activated LX2 was cultured in LX2 cell
medium, B10-NC-CM or TSG-6-CM. In addition, those
cells cultured in TSG-6-CM were treated with TSG-6 anti-
body (10 μg/ml) or control IgG (10 μg/ml). These experi-
ments were repeated three times [25].
Statistical analysis
Results are expressed as the mean ± standard deviation
(SD). Statistical differences were determined by Student’s
t-test or one-way analysis of variance (ANOVA) using the
SPSS statistics 20, followed by Scheffe’ post hoc test. P-
values <0.05 were considered to be statistically significant.
Results
Generation of TSG-6-overrexpressing MSCs
To investigate the effect of TSG-6 in liver injury, we gener-
ate hMSCs stably expressing TSG-6 based on immortalized
fetal bone marrow hMSCs (B10) [21], using a lentivirus de-
livery system. The stable expression of TSG-6 in hMSCs
was confirmed by a higher expression level of TSG-6 mRNA
(Figure 2A) and protein (Figure 2B) in TSG-6-hMSCs. More
importantly, a detectable level of TSG-6 protein was also
found in the CM from TSG-6-hMSCs (Figure 2B, lower
Figure 2 Production of MSC overexpressing TSG-6. (A) The mRNA level of TSG-6 in CSII-EF-MCS- and CSII-EF-TSG-6-expressing hMSC cells was
determined via real-time PCR. (B) TSG-6 stable transfection to hMSCs was confirmed by immunoblotting for Wip1 (top panel). Equal protein loading
was verified by α-tubulin immunoblotting (middle panel). Secretion of TSG-6 in hMSCs was confirmed in the conditioned media by immunoblotting
for TSG-6 (bottom panel). (C) TSG-6 expression in TSG-6-hMSC was validated by immunostaining with anti-TSG-6 antibody (left panel, TSG-6). GM130
was counterstained as a Golgi complex marker (middle panel, GM130). DAPI was used for nuclear counterstaining (right panel, DAPI). (D) CD4+ T cells
from mouse splenocytes were cultured in the presence of CD3 antibody (1 μg/ml of α-CD3). T cells proliferation was determined by FACS analysis after CFSE
staining. CM either from hMSCs (B10) or TSG-6-hMSCs were incubated for three days in the presence of CD3 antibody. Culture medium for hMSCs was used
as the control medium. CFSE, carboxyfluorescein succinimidyl ester; CM, conditioned medium; DAPI, 4′,6-diamidino-2-phenylindole; FACS, fluorescence
activated cell sorting; hMSCs, human mesenchymal stem cells; MSCs, mesenchymal stem cells; TSG-6, tumor necrosis factor-inducible gene 6 protein.
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Golgi complex, a distinct signal from the Golgi complex
(determined by GM130, a typical Golgi marker) in TSG-6-hMSCs was clearly observed (Figure 2C). To examine the
immune-modulatory activity of TSG-6 secreted from TSG-
6-hMSCs, splenocytes freshly isolated from the mouse
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hMSCs (TSG-6 B10). While activated CD4+ T cells by CD3
antibody underwent active proliferation, proliferation of
CD4+ T cells was markedly reduced following treatment
with CM from either hMSC or TSG-6-hMSCs, compared
to control medium even after CD3 stimulation. Of interest,
CM from TSG-6-hMSCs appeared to be more effective in
suppressing Tcell proliferation (Figure 2D).
TSG-6 attenuates liver injury
To examine whether TSG-6 influenced liver regeneration,
mice were treated with CCl4 to induce acute liver injury
and i.p. injected with TSG-6-rich CM (TSG-6-CM) (CCl4 +Figure 3 Effects of TSG-6 on liver histomorphology and function in CCl4-tr
infiltration of inflammatory cells in CCl4-treated mice with or without NC (negativ
injuries were reduced in CCl4 mice treated with TSG-6-CM (CCl4 + TSG-6). The rep
CCl4:CCl4-treated mice/ CCl4 +NC: CCl4-treated mice with NC-CM). (B) Relative liv
(D) QRT-PCR analysis for G6pc of liver mRNA from normal (CTRL), CCl4, CCl4 with
versus CTRL, #P <0.05 versus CCl4, $P <0.05 versus CCl4 +NC-CM). ALT, alanine am
G6pc, glucose-6-phosphatase; TSG-6, tumor necrosis factor-inducible gene 6 protTSG-6-CM: TSG-6 group) or TSG-6-poor CM (NC-
CM) (CCl4 + NC-CM: NC group). Liver sections from
those mice were examined for the effect of TSG-6 using H
& E staining. CCl4-treated mice showed severe cytoplas-
mic vacuolation, microvesicular fatty changes, loss of cel-
lular boundaries, infiltration of inflammatory cells around
the central vein and in the portal areas, congestion in the
sinusoids, and necrosis of the liver cells. Interestingly,
those abnormal morphological changes were remarkably
ameliorated and restored to almost normal morphology in
the TSG-6 group, compared to the NC and CCl4 groups
(Figure 3A). The ratio of liver weight versus body weight
(LW/BW) declined in mice in the CCl4 and NC groupseated mice. (A) H & E staining shows the extensive cellular damage and
e control: mock transfected cell)-conditioned medium (CM). Those cellular
resentative images are shown at × 40 (CTRL: corn-oil-treated control mice/
er weight / body weight of mice. (C) The values of AST and ALT are graphed.
NC-CM (NC) or TSG-6-CM (TSG-6) (n ≥4 mice / group) (ANOVA, *P <0.05
inotransferase; ANOVA, analysis of variance; AST, aspartate aminotransferase;
ein.
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control, *P <0.05), whereas there was no significant change
of LW/BW between the control and TSG-6 groups
(Figure 3B). In addition, CCl4-treated mice with or without
NC-CM had elevated serum AST and ALT, whereas
CCl4-treated mice withTSG-6-CM had alleviated AST (con-
trol-31.32 ± 1.74, CCl4-95.72 ± 7.23, NC-85.09 ± 8.59 and
TSG-6-5.84 ± 6.28) and ALT (control-33.95 ± 3.09, CCl4-
104.52 ± 3.09, NC-94.33 ± 4.79, and TSG-6-73.25 ± 15.03)
(Figure 3C). Furthermore, the RNA level of glucose-6-
phosphatase (G6pc), which is known to be an essential en-
zyme for glycolysis, was similar between the control and
TSG-6 groups (Figure 3D).
To determine if these changes in the liver repair process
were associated with the hepatocyte proliferation, liver
sections from CM-treated mice with CCl4 were stained
for Ki67, a marker of S phase [26]. The injured livers of
mice with or without NC-CM mainly had Ki67-positive
hepatic stellate-looking cells, whereas livers of mice with
TSG-6-CM largely contained Ki67-positive hepatocytic
cells (Figure 4). Because liver damage leads to expansionFigure 4 Expansion of Ki67-positive hepatocytic cells in liver of mice
representative control, CCl4, CCl4 + NC, and CCl4 + TSG-6 mice (×40). (B) Ki6
versus CTRL, #P <0.05 versus CCl4, $P <0.05 versus CCl4 + NC-CM). ANOVA,
immunohistochemistry; NC, negative control; TSG-6, tumor necrosis factor-iof liver progenitors [26,27], it was further investigated
whether reduced liver injuries influenced the proliferation
of liver progenitors. As assessed by IHC for PanCK and
Sox9, two different markers of liver progenitors [28-30],
both the CCl4 and NC groups exhibited an expansion of
hepatic progenitors compared to the control and TSG-6
groups (Figure 5). Therefore, these results suggested that
TSG-6 promoted the repair process into the normal
restoration of the liver by contributing to hepatocyte
proliferation.
Decreased hepatic fibrosis in TSG-6 treated mice
Because CCl4 is a well-known chemical that induces
hepatocyte injury and inflammation, promoting collagen
deposition, we examined whether TSG-6 might exert an
anti-inflammatory effect, thereby decreasing fibrogenesis
in this animal model. The expression of inflammation
markers, such as tnfα, il-1β, cxcl1 and cxcl2, was signifi-
cantly higher in the CCl4 and NC groups than in the
TSG-6 group (Figure 6). The RNA expression of the fi-
brotic markers, tgf-β, α-sma and collagen α1, was greatlywith CCl4 + TSG-6 treatment. (A) IHC for Ki67 in liver sections from
7-positive hepatocytes were counted and graphed (ANOVA, *P <0.05
analysis of variance; CM, conditioned medium; CTRL, control; IHC,
nducible gene 6 protein.
Figure 5 TSG-6 decreases the proliferation of hepatic progenitors in the liver damaged with CCl4. IHC for PanCK and Sox9 in liver sections
from representative control, CCl4, CCl4 + NC, and CCl4 + TSG-6 mice (×40). IHC, immunohistochemistry; NC, negative control; PanCK, pancytokeratin;
TSG-6, tumor necrosis factor-inducible gene 6 protein.
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livers, whereas those genes were downregulated in in-
jured livers treated with TSG-6-CM (Figure 7A). In line
with mRNA expression, the protein level of TGF-β and
α-SMA decreased in the TSG-6 treated group, showing
the baseline TGF-β and α-SMA expression in healthy
livers (Figure 7B, C). In addition, IHC staining for α-
SMA clearly showed that the accumulation of activated
hepatic stellate cells in livers of the CCl4 and NC groups
was reduced in the livers of the TSG-6 group (Figure 7D).
Therefore, these results demonstrated that the TSG-6
attenuated both inflammation and the expansion of
fibrous matrix in the injured liver.TSG-6 induced inactivation of hepatic stellate cells
Fibrosis is the excessive accumulation of collagen and other
extracellular matrix components, and the accumulated fi-
brotic tissues disarrange the liver constitution. A change in
the hepatic structure induces hepatic dysfunction, leading to
the death of the patient. Several types of cells, such as bone
marrow-derived cells, circulating fibrocytes, and portal fibro-
blasts, are known to contribute to hepatic fibrosis by transi-
tioning to myofibroblasts. Particularly, activated hepatic
stellate cells are primary sources of myofibroblastic cells
promoting fibrogenesis. Hence, we investigated whether
TSG-6 was involved in the activation of hepatic stellate cells
because our data showed regressed fibrosis in the TSG-6
Figure 6 TSG-6 decreases the inflammation in the liver damaged with CCl4. QRT-PCR analysis of mouse liver for tnfα, il-1β, cxcl1 and cxcl2. Mean± SD
results are graphed (n ≥4 mice/group) (ANOVA, *P <0.05 versus CTRL, # P <0.05 versus CCl4, $P <0.05 versus CCl4 +NC-CM). ANOVA, analysis of variance; CM,
conditioned medium. CTRL, control; NC, negative control; SD, standard deviation; TSG-6, tumor necrosis factor-inducible gene 6 protein.
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decreased expression of activated markers of hepatic stellate
cells, such as tgf-β, vimentin and collagen α1, whereas cells
cultured in NC-CM or LX2 cell medium had greatly in-
creased expression of those markers. In addition,
neutralization of TSG-6 by the TSG-6 antibody effect-
ively induced the expression of those markers in LX2
cells (Figure 8A). Oil Red O staining showed cytoplasmic
lipid droplets, the morphologic hallmark of inactivated
hepatic stellate cells, in the LX2 cells cultured in TSG-6-
CM, whereas those lipid droplets were not seen in cells
cultured in NC-CM or LX2 cell medium (Figure 8B).
To assess whether TSG-6 directly influenced liver res-
toration in mice with CCl4 damage, TSG-6-CM neutral-
ized with TSG-6 antibody was injected in CCl4-treated
mice (TSG-6 + Ab group) (Figure 1B). The livers of the
TSG-6 + Ab group had severe hepatic injuries, whereas
the livers from the TSG-6 or TSG-6 + IgG groups showed
almost normal morphology without distinct morpho-
logical differences between the two groups, as examined
by H & E staining (Figure 9A). The ratio of liver weight/
body weight (LW/BW) decreased and serum AST and
ALT increased in mice in the TSG-6 + Ab group, com-
pared with mice in the TSG-6 or TSG-6 + IgG group
(Figure 9B, C, D). The RNA expression of g6pc was also
down-regulated in the TSG-6 + Ab group (Figure 9E). Fur-
thermore, the neutralization of TSG-6 by TSG-6 antibody
led to an increase in the fibrotic markers, tgf-β, α-sma and
collagen α1, as assessed by quantitative real-time PCR
(Figure 9F). In addition, the expression of inflammation
markers, tnf-α, il-1β, cxcl1 and cxcl2, was higher in the
TSG-6 neutralized group than in the TSG-6 or TSG-6 +
IgG groups. Taken together, these data suggested that
TSG-6 induced the inactivation of hepatic stellate cells,
contributing to the ameliorated fibrosis in mice.Discussion
Acute liver failure shows a higher inflammatory response
to liver damage, which impairs the parenchymal function
that extends into systemic organ failure, eventually leading
to death [16,31]. Thus, researchers must develop new treat-
ments for acute liver disease. The potential for MSCs to dif-
ferentiate into hepatocytes and their immunomodulatory
capabilities make MSCs an attractive choice in the therapy
of acute or chronic liver diseases [9]. Several clinical trials
are currently being performed to investigate the therapeutic
potential of MSCs in the treatment of chronic liver diseases,
such as Hepatitis B or C virus-infected liver or alcoholic
liver with cirrhosis [32-34]. Previous studies have shown
that transplanted MSCs replace the damaged cells and re-
populate in the injured tissues or organs [35]. However, the
number of long-term substituted MSCs is open to dispute
because those numbers differed depending on the injury
models, the transplant route and time, and so on [8].
Nevertheless, it seems to be uncontroversial that MSCs and
the CM from MSCs contribute to improving damage from
liver injuries [9,36]. The transplanted MSCs help or allow
the survival or proliferation of endogenous cells by direct
contact or modulating inflammation [9]. MSCs are known
to alleviate acute and chronic liver injury by changing the
disease environment; for example, they decreased inflam-
mation and cell death, but they increased cell proliferation
[9]. In the present study, TSG-6 released by MSCs
suppressed the proinflammatory signal and reduced the
collagen accumulation which was likely due to the inactiva-
tion of hepatic stellate cells by TSG-6 in the acute liver in-
jury of mice.
Although the anti-inflammatory action of TSG-6 is
shown to promote improvement in the damaged tissue
[14,37], this effect of TSG-6 in the liver remains unknown.
Thus, we investigated whether TSG-6 might be involved in
Figure 7 Reduced fibrosis in the TSG-6 treated liver. (A) QRT-PCR analysis of liver mRNA for tgf-β, α–sma and collagen-α1 (n ≥4 mice/group). Mean±
SD results are graphed. (B) and (C). Western blot analysis of TGF-β (25 kDa: processed form) (inducer of fibrosis) and α-SMA (fibrogenic marker) (GAPDH was
used as an internal control) (n ≥4 mice/group). Data shown represent one of three experiments with similar results (B: Immunoblot/ C: Band density of TGF-β
and α-SMA). Data represent the mean± SD of three independent experiments. (D) IHC for α-SMA in liver sections from representative control, CCl4, CCl4 +
NC, and CCl4 + TSG-6 mice (×40) (ANOVA, *P <0.05 versus CTRL, #P <0.05 versus CCl4, $P <0.05 versus CCl4 +NC-CM). ANOVA, analysis of variance; CM,
conditioned medium; CTRL, control; IHC, immunohistochemistry; NC, negative control; SD, standard deviation; TSG-6, tumor necrosis factor-inducible gene
6 protein.
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Figure 8 TSG-6 blocks activation of hepatic stellate cells. (A) QRT-PCR analysis for tgf-β, vimentin and collagen-α1 in LX2 cells which were
cultured in LX2 cell medium (LX2), NC-CM (LX2 + NC), TSG-6-CM with (LX2 + TSG-6 + Ab) or without TSG-6 antibody (LX2 + TSG-6). IgG was used
as a negative control for TSG-6 antibody (LX2 + TSG-6 + IgG). Mean ± SD results are graphed. Data represent the mean ± SD of three independent
experiments (ANOVA, *P <0.05 versus LX2, #P <0.05 versus NC, $P <0.05 versus TSG-6 + Ab). (B) Oil Red O staining in LX2 cells cultured in LX2,
NC-CM, or TSG-6-CM (original magnification × 40). ANOVA, analysis of variance; CM conditioned medium; IgG, immunoglobulin G; NC, negative
control; SD, standard deviation; TSG-6, tumor necrosis factor-inducible gene 6 protein.
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Our results demonstrated that TSG-containing CM led to
liver regeneration. This protective effect of TSG-6 was also
observed in another experimental model; specifically, chori-
onic plate-derived MSCs (CP-MSCs) that shared common
characteristics and differentiation potentials with bone
marrow-MSCs promoted liver regeneration in rat livers that
had been chronically damaged by CCl4 [38,39]. In this
model, the CP-MSCs contained a greater expression of
TSG-6, and the regenerating liver transplanted with CP-
MSC showed a higher expression of TSG-6, compared to a
non-transplanted liver (Additional file 1: Figure S1). This
evidence strongly supported the regenerative effect of TSG-
6 in the liver.
In this experimental model, acutely injured livers showed
distorted histomorphology, changes in LW/BW, and in-
creased levels of the liver enzymes, ALT and AST, but TSG-
6-CM treatment attenuated those abnormalities and evencontributed to restoring the liver function which was
evidenced by g6pc expression. G6pc hydrolyzes glucose-6-
phosphate, which is the central metabolite of glucose metab-
olism [40]. The data showing almost normal glucose meta-
bolic homeostasis in TSG-6-CM treated livers strongly
support the restoration of liver function through the action
of TSG-6. In addition, the downregulated proinflammatory
factors in the TSG-6-CM group demonstrated that TSG-6
exerted an anti-inflammatory effect on the CCl4-treated
mouse livers.
Liver injury induces activation of hepatic stellate cells and
proliferation of progenitors [16,26]. Activated stellate cells
have been shown to be associated with the proliferation of
hepatic progenitors [27,41]. In Ki67 staining, more Ki67-
positive hepatocytic cells and fewer Ki67–positive hepatic
stellate cells were observed in livers of the TSG6 group.
Compared with liver of CCl4 +TSG-6-treated mice, livers of
CCl4 or CCl4 +NC-treated mice contained more PanCK-
Figure 9 Neutralization of TSG-6 by TSG-6 antibody attenuates the restoration effect of TSG-6 in liver of CCl4 + TSG-6-treated mice. (A) H & E
staining shows the histomorphological changes in CCl4 + TSG-6-treated mice with (CCl4 + TSG-6 + TSG-6 antibody) (CCl4 + TSG-6 + IgG) without TSG-6
antibody (CCl4 + TSG-6) or IgG. The representative images were shown at × 40. (B) Relative liver weight/body weight of mice. (C), (D) The values of AST and
ALT are graphed. (E, F, G) QRT-PCR analysis for G6pc (E), the fibrotic markers (F), tgf-β, α–sma and collagen-α1, the inflammation markers (G), tnfα, il-1β, cxcl1
and cxcl2, of liver mRNA from the treated mice (n ≥4 mice / group). Mean± SD results are graphed (ANOVA, *P <0.05 versus TSG-6, #P <0.05 versus TSG-6 +
Ab). ALT, alanine aminotransferase; ANOVA, analysis of variance; AST, aspartate aminogransferase; G6pc, glucose-6-phosphatase; IgG, immunoglobulin G; SD,
standard deviation; TSG-6, tumor necrosis factor-inducible gene 6 protein.
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We examined if these changes in the activation and /or pro-
liferation of hepatic stellate cells and the reduced liver dam-
age influenced the proliferation of progenitors. As we
expected, decreased expansion of progenitors was ob-
served in livers of the TSG-6 group, compared to the
CCl4 and NC groups. Therefore, these results indicated
that micro-environmental changes by TSG-6 might
contribute to the proliferation of hepatocytes by pro-
tecting hepatocytes from injury. Also, it could be pos-
sible that TSG-6 might promote differentiation of
progenitors into hepatocytes. However, neither the direct ef-
fects of TSG-6 on progenitors nor the progenitor prolifera-
tion at the early time point after CM injection was
investigated in the present studies. Hence, further studies
are required to provide the evidence for this possibility.
The degree of inflammatory response parallels the
fibrotic severity in the liver [42]. The activated hepatic
stellate cells play a key role in hepatic fibrogenesis
[43,44]. Both RNA and the protein level of fibrotic
markers were downregulated in the livers of TSG-6-
CM-treated mice. Activated LX2 cultured in TSG-6-CM
showed a decreased expression of fibrotic markers and
an increased number of lipid drops. Conversely, the
addition of the TSG-6 antibody neutralized these inhibi-
tory effects of TSG-6 on the activation of LX2, although
this addition was less effective than NC-CM. It is pos-
sible that the TSG-6 antibody does not block all TSG-6,
and the amount of TSG-6 that escaped blocking by the
antibody is higher than it is in NC-CM. One explanation
is that the TSG-6-overexpressing MSCs and the CM of
those cells show a greater expression of TSG-6, but
TSG-6 is rarely detected in NC and NC-CM. Hence,
these results proved that TSG-6 influenced the activa-
tion of hepatic stellate cells, suggesting that TSG-6 con-
tributed to the reduced fibrosis in damaged livers of
mice.
CM obtained from empty plasmid-transfected MSC was
less protective in the damaged liver. In line with our finding,
Herrera et al. [7], demonstrated that both human liver stem
cells (HLSCs) and HLSC-CM improved liver injury and had
a protective effect for liver, but MSC-CM was totally inef-
fective in their experimental model [7]. In addition, they
employed the concentrated CM in their experimental model
of liver injury, like other researchers did. However, the CM
used in the present studies was not concentrated. MSC-CM
includes many kinds of cytokines, growth factors, and even
microparticles [37,45]. Because we used 0.5 ml CM per
mouse from a total 12 ml CM which was collected at 70%
to 80% confluent cells, this small volume of CM seemed to
contain a significantly lower amount of those factors, com-
pared to the concentrated CM. Hence, the effects of other
factors were likely negligible in this model. Also, we exam-
ined the regulation of hepatic stellate cells by TSG-6, notthe apoptosis of hepatocytes, and demonstrated that hepatic
stellate cells were inactivated in TSG-6-CM, but not in NC-
CM or TSG-6-CM with the TSG-6 antibody. Furthermore,
CCl4-treated mice injected with TSG-6-CM incubated with
TSG-6 antibody induced the liver damage which was ame-
liorated in CCl4-treated mice with TSG-6-CM. These results
suggest that the reduced inflammation and fibrosis caused
by TSG-6 might provide a beneficial microenvironment
which contributes to the proliferation or survival of hepato-
cytes, leading to liver regeneration.
Conclusions
Our results first demonstrate that TSG-6 influences liver
regeneration and place TSG-6 into the central position in
the regulation of liver regeneration. The protective and/or
improving effects of TSG-6 on the damaged liver through
attenuating inflammation and fibrosis help to develop novel
therapeutic approaches to treat acute liver failure. However,
further studies are required to examine the underlying
mechanism for the regenerative actions of TSG-6 and those
effects in other liver diseases, including chronic diseases.
Additional file
Additional file 1: Figure S1. Chorionic plate-derived MSCs express
TSG-6. (A) QRT-PCR analysis for TSG-6 in CP-MSCs (B) QRT-PCR analysis for
CP-MSCs-transplanted rat liver which had been chronically damaged by
CCl4 (*P <0.05, **P <0.005) (Transplantation: CCl4-treated rats with CP-MSCs
transplantation).
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